Forte Biosciences (FBRX) EBT (2016 - 2026)
Forte Biosciences' (FBRX) quarterly EBT came in at -$21.8 million in Q1 2026, down 39.01% year-on-year from -$35.7 million in Q1 2025, and up 11.58% on a QoQ basis from -$24.6 million in Q4 2025.
Forte Biosciences (FBRX) EBT (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of EBT data on file, last reported at -$21.8 million in Q1 2026.
- On a quarterly basis, EBT fell 39.01% year-over-year to -$21.8 million in Q1 2026; TTM through Mar 2026 was -$106.8 million, a 139.46% decrease from a year earlier, with the FY2025 full-year figure at -$72.5 million, down 1485.06% from the prior year.
- EBT for Q1 2026 stood at -$21.8 million, up from -$24.6 million in the prior quarter.
- Over the last five years, EBT for FBRX reached as high as -$2.8 million in Q1 2022 and fell as low as -$35.8 million in Q3 2025.
- Historically, EBT has averaged -$12.1 million across 5 years, with a median of -$8.7 million in 2024.
- Across the five-year window, EBT jumped 90.32% in 2022 and slumped 313.47% in 2025, its largest moves.
- Year by year, EBT stood at -$5.0 million in 2022, then dropped by 28.12% to -$6.4 million in 2023, then declined by 15.93% to -$7.4 million in 2024, then slumped by 231.19% to -$24.6 million in 2025, then gained by 11.58% to -$21.8 million in 2026.
- Per Business Quant data, the three most recent EBT figures were -$21.8 million in Q1 2026, -$24.6 million in Q4 2025, and -$35.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 259.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.49 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Forte Biosciences | 174.08 Mn | 115.88 Mn | - | -21.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.76 Mn |
| Dec 31, 2025 | -24.61 Mn |
| Sep 30, 2025 | -35.79 Mn |
| Jun 30, 2025 | -24.61 Mn |
| Mar 31, 2025 | -15.66 Mn |
| Dec 31, 2024 | -7.43 Mn |
| Sep 30, 2024 | -8.66 Mn |
| Jun 30, 2024 | -12.85 Mn |
| Mar 31, 2024 | -7.83 Mn |
| Dec 31, 2023 | -6.41 Mn |
| Sep 30, 2023 | -10.22 Mn |
| Jun 30, 2023 | -9.12 Mn |
| Mar 31, 2023 | -6.93 Mn |
| Dec 31, 2022 | -5.00 Mn |
| Sep 30, 2022 | -3.52 Mn |
| Jun 30, 2022 | -3.24 Mn |
| Mar 31, 2022 | -2.82 Mn |
| Dec 31, 2021 | -12.89 Mn |
| Sep 30, 2021 | -8.74 Mn |
| Jun 30, 2021 | -28.92 Mn |